# Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

> **NCT04940286** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Borderline Resectable Pancreatic Adenocarcinoma
- Resectable Pancreatic Adenocarcinoma
- Stage IA Pancreatic Cancer AJCC v8
- Stage IB Pancreatic Cancer AJCC v8
- Stage IIA Pancreatic Cancer AJCC v8
- Stage IIB Pancreatic Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **BIOLOGICAL:** Oleclumab

## Key facts

- **NCT ID:** NCT04940286
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-28
- **Primary completion:** 2027-10-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04940286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04940286, "Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04940286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*